This site and its domain are for sale. Email the owner if you want to talk about it.

bioclocktest.com

TruAge and TruDiagnostic: What the Test Reports

A million DNA sites go in, 64 numbers come out, and the evidence that lowering them helps you is still missing.

A laboratory technician's gloved hands placing a saliva or blood collection tube into a rack beside a row of sample vials.

TruDiagnostic says its test reads more than 1 million sites on your DNA. Then it hands back 64 numbers. That is a pretty aggressive compression ratio, and most of what is interesting about the product lives in the space between the million and the 64.

When people type “truage” into a search box, they mean TruDiagnostic’s epigenetic age test. Here is the plain answer. The product combines three epigenetic clocks, called OMICmAge, SymphonyAge and DunedinPACE, and the company says the report covers 64 “longevity biomarkers” across biological age, aging speed and organ-specific aging for 11 body systems, including brain, heart and liver. DunedinPACE has a published academic record you can read on its own terms. For the other two, the company reports “50+ peer-reviewed publications” supporting its products and more than 80 academic and research partnerships, but those counts do not by themselves settle how well each clock holds up. On that question the record is not settled.

What the TruAge report contains

Here is what an epigenetic clock does, stated as plainly as I can. It looks at a lot of spots on your DNA, notes which ones carry a particular chemical tag, compares the pattern to a large group of people whose ages and health are known, and guesses something about you. That is called an epigenetic clock. (The chemistry has its own article on this site, and so does the general question of what these tests measure.)

TruAge runs three of these. OMICmAge, in TruDiagnostic’s description, is a “multi-omic-informed methylation clock” that compares your biological age to your chronological age. SymphonyAge estimates a biological age for each of 11 organ systems. DunedinPACE does not give you an age at all. It gives you a speed: how fast you are aging, as a rate.

So the report is less like a single verdict and more like the back of a baseball card, with an overall number, a batting average and a column of splits by organ. That’s fine. A baseball card is a useful object. It does help to know which stats have been around long enough to mean something, though.

Why one test needs three clocks

The chain starts with researchers, who get rewarded (in grants, citations and tenure, the usual currency) for building a new clock that does something the old ones did not. The Horvath clock, published in 2013, was the landmark: it predicted age across many tissues and cell types. The Hannum clock was built on 482 people aged 19 to 101, all of Caucasian or Hispanic ethnicity. Both picked their DNA sites using a statistical method called elastic net regression, aimed at producing the most accurate estimate of chronological age.

This creates a weird problem. A clock that perfectly predicts your chronological age is perfectly useless to you. You already know your birthday. The interesting part is the error, the gap between what the clock says and what your driver’s license says, and the next generation of clocks was trained to make that gap mean something (risk of disease, rate of decline, etc.).

The accuracy race also keeps going on its own track. One 2022 study built clocks with new feature-selection methods that beat the Hannum, Horvath and Weidner clocks on two outside datasets, and its most predictive clock used only 35 DNA sites, with an R-squared of 0.87. Thirty-five. TruDiagnostic reads more than a million. Those are different jobs, I suppose, but it is worth knowing that a long list of sites is not the same thing as a better answer.

Now the company link. A company selling a test wants its report to be fuller than the next company’s, and organ ages are a natural way to get there. (“Hey, what if the brain had its own number,” is a sentence I am inventing, but somebody in product said a version of it somewhere.) Elysium Health’s Index test, for comparison, reports ages for nine body systems. TruAge reports 11. More rows on the card.

In fairness, TruDiagnostic at least names its clocks, which is more than the field usually manages. As The Scientist put it, “most companies offering biological age test kits do not detail which epigenetic clock they use.”

How DunedinPACE was built to repeat itself

Of the three clocks, DunedinPACE is the one designed most directly around a measurement problem. Its predecessor, DunedinPoAm, was published by Belsky and colleagues in 2020 as a single-time-point blood test of the pace of aging. DunedinPACE kept the idea and changed the inputs: its builders threw out DNA sites with low test-retest reliability before training, then ran elastic net on what was left. The result showed reliability above 0.90.

Why does that matter? Because a clock you take twice should say roughly the same thing twice. Elysium Health (which sells a competing test, so read its numbers with that in mind) reported that technical replicates of the Horvath, Hannum and PhenoAge clocks deviated by three to nine years between measurements of the same sample, and that its own Index test agreed within zero to 1.5 years. A separate platform called TranslAGE evaluated the technical and biological reliability of 18 epigenetic clocks. The reliability question has its own article on this site; the short version is that some clocks wobble more than others, and DunedinPACE was engineered specifically not to.

There is also a sample detail. Almost all clocks in commercial tests are trained on blood. A test that matches its sample type to its training data is, at least, not fighting its own inputs.

What published validation shows for TruAge and its clocks

Here is where the chain gets interesting. The AMA Journal of Ethics, in a December 2025 commentary, says these tests have been shown to be fairly reliable indicators of a person’s risk of developing certain age-related diseases. That is a real finding about association. People with faster clocks, on average, get sicker.

On the other hand, the thing a customer most wants to know is different. The customer wants to know whether making the number go down makes them healthier. A 2026 systematic review of geroscience intervention trials looked for exactly that, trial-level validation that clocks work as surrogate endpoints, and found none.

This is not a small distinction. The TRIIM trial used four epigenetic clocks and claimed to be the first report of an increase in predicted human lifespan from a currently accessible intervention, based on epigenetic age estimation. Its follow-up, TRIIM-X, added control groups to test biomarker variability and the contribution of individual medications, which the original did not have. So the field is aware of the gap. It is just still standing in it.

And the incentive at this link is clear. Anyone selling an intervention wants a number that moves. A clock that moves is a clock you can sell twice.

Where the incentive chain ends up

Everyone in this chain is acting sensibly from where they stand. Researchers publish better clocks because that is the job. Companies bundle several clocks and add organ ages because a fuller report is a better product. Customers buy the test because a number about your own aging is interesting, and doctors look at the results because patients bring them in.

Anyway, the AMA commentary describes where this can arrive. A healthy 56-year-old, identified as AA, received a direct-to-consumer result (not identified as a TruAge result) saying he was “biologically 65-years-old.” He then followed the manufacturer’s recommendations and began courses of the company’s brain health and cellular repair supplements. The test and the supplements were, in the corporate-structure sense, related.

The commentary’s view is that these tests cannot tell us how old a person “really” is, and it calls biological age a fiction. It asks companies to be clearer about how the tests work, how reliable they are and what they can and cannot show, and warns that results can cause psychological harm and make age-related discrimination look justified. That is a strong position. I guess you can read it as the last link of the chain looking back at the first.

Nobody in the chain set out to produce that patient. Each link just got paid for its own piece: the clock, the report, the number, the next step.

A million sites go in. Sixty-four numbers come out. The compression was never the aggressive part.

Sources

  1. TruDiagnostic™ Biological Age Test
  2. About TruAge
  3. Epigenetic Clocks Power Biological Age Data, But Why Do Results Differ Across Tests? | The Scientist
  4. What Are the Most Ethically Salient Implications of Epigenetic Age Testing? – Dec 2025 | Journal of Ethics | American Medical Association
  5. Reversal of epigenetic aging and immunosenescent trends in humans
  6. DunedinPACE, a DNA methylation biomarker of the pace of aging | eLife
  7. The Science Behind Index | Elysium Health
  8. Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial | Clinical Research Trial Listing ( Epigenetic Aging | Immunosenescence ) ( NCT04375657 )
  9. Choosing Epigenetic Clock Models: Horvath, Hannum, PhenoAge, GrimAge and Beyond - CD Genomics
  10. Concordance between changes in epigenetic clocks and changes in clinical outcomes in geroscience intervention trials: A systematic review
  11. DunedinPACE | Moffitt & Caspi: Genes, Environment, Health, Behavior
  12. Epigenetic Clock | UCSF SMN
  13. What Are the Most Ethically Salient Implications of Epigenetic Age Testing?
  14. Biological versus Technical Reliability of Epigenetic Clocks and Implications for Disease Prognosis and Intervention Response
  15. Novel feature selection methods for construction of accurate epigenetic clocks

Bio Clock Test explains published research. It is not medical advice and it does not diagnose anything. We never recommend a test, a supplement or a treatment. Talk to a clinician about your health.

Read next